Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Arrow is the marketing partner in US
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
